HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) as well as an adjournment of the Annual Meeting as outlined below.
Related news for (HSCS)
- HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
- Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
- HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
- HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
- HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 – Featuring CEO Andrew Simpson
